JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:2554-2560, doi:10.1016/j.jacc.2006.04.039 (Published online 27 April 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mancini, G.B. J.
Right arrow Articles by Brophy, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mancini, G.B. J.
Right arrow Articles by Brophy, J. M.

Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease

G.B. John Mancini, MD, FRCP(C), FACC*,*, Mahyar Etminan, PharmD, MSc{ddagger}, Bin Zhang, MSc§, Linda E. Levesque, BScPhm, MSc§, J. Mark FitzGerald, MD, FRCP(C){dagger} and James M. Brophy, MD, PhD, FRCP(C), FACC§

* Division of Cardiology, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
{dagger} Division of Respiratory Medicine, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
{ddagger} Centre for Clinical Epidemiology and Evaluation, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
§ Departments of Medicine, Epidemiology, and Biostatistics, McGill University Health Centre, McGill University, Montreal, Quebec, Canada


Figure 1
View larger version (25K):

[in a new window]
  		Figure 1 Fully adjusted risk ratios are plotted for the end points of hospitalization for chronic obstructive pulmonary disease (COPD), myocardial infarction (MI), death, and MI or death. Treatments analyzed were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), statins (hydroxymethylglutaryl CoA reductase inhibitors [HMG-CoA]), and the combination of statins with ACE inhibitors or ARBs (combination) in the population of COPD patients with prior revascularization (high risk). Results including steroid users are in the right panel.

 

Figure 2
View larger version (25K):

[in a new window]
  		Figure 2 Fully adjusted risk ratios are plotted for the end points of hospitalization for chronic obstructive pulmonary disease (COPD), myocardial infarction (MI), death, and MI or death. Treatments analyzed were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), statins (hydroxymethylglutaryl CoA reductase inhibitors [HMG-CoA]), and the combination of statins with ACE inhibitors or ARBs (combination) in the population of COPD patients without previous MI and newly treated with nonsteroidal anti-inflammatory drugs (low risk). Results including steroid users are in the right panel.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.